Nachrichten zur Bristol-Myers Squibb Co. Aktie

…

Image source: The Motley Fool.DATEMonday, Nov. 3, 2025 at 4:30 p.m. ETCALL PARTICIPANTSPresident and Chief Executive Officer — Helen TorleySenior…

MAINZ (dpa-AFX) - Die Zusammenarbeit mit dem US-Konzern Bristol-Myers Squibb (BMS) bringt Biontech reichlich Geld für die weitere…

Image source: The Motley Fool.DateOct. 29, 2025, 5:30 p.m. ETCall participantsChief Executive Officer and President — Adair Fox-MartinChief Financial Officer…

Image source: The Motley Fool.DateOct. 29, 2025 at 5:30 p.m. ETCall participantsChairman and Chief Executive Officer — Satya NadellaChief Financial…

…

…

Das Übernahmekarussell im Biotechnologie-Sektor dreht sich dynamisch weiter. Nachdem Novo Nordisk die milliardenschwere Übernahme des AKTIONÄR-Tipps Akero am Donnerstag bekanntgegeben…

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial…

Bristol Myers Squibb (BMY) reached $45.1 at the closing of the latest trading day, reflecting a +2.15% change compared to…

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be…

…

Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.…

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $45.6, denoting a -1.19% move from…

Key PointsGAAP revenue was $4.4 million for Q2 2025 and Revenue plummeted to $4.4 million in the second quarter of…

…

…

…

NEW YORK (dpa-AFX) - Die Aussicht auf politischen Druck auf die Medikamentenpreise in den USA hat am Donnerstag die Branche…

Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most established and best-selling brands,…

Explore the exciting world of Bristol Meyers Squibb (NYSE: BMY) with our contributing expert analysts in this Motley Fool Scoreboard…

AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen…

Das Unternehmen wird mit fünf potenziellen Behandlungen für Autoimmunerkrankungen beginnen, die es von Bristol Myers Squibb einlizenziert hat. Bristol Myers…

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs,…

Key PointsCompanies must pass key tests to be included in the Schwab U.S. Dividend Equity ETF.This fund has averaged a…

Bristol Myers (BMY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Bristol Myers Squibb (BMY) closed at $48.02 in the latest trading session, marking a +2.85% move from the prior day.…

The companies new effort would bypass traditional middlemen to cut the drugs monthly cost from a list price of around…

Bristol Myers Squibb (BMY) closed at $47.17 in the latest trading session, marking a +1.59% move from the prior day.…

…

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $47.66, denoting a +1.32% move from…

Key PointsBuffetts Berkshire Hathaway portfolio includes only one ultra-high-yield stock.However, his "secret portfolio" is loaded with ultra-high-yielders.The best of the…

Key PointsSoundHound AI and C3.ai are pure-play artificial intelligence (AI) software companies with massive opportunities ahead.SoundHound AI stock is more…

• BioNTech sichert sich 3,5 Milliarden US-Dollar durch Partnerschaft mit Bristol Myers Squibb für Krebsantikörper BNT327• Sofortzahlung von 1,5 Milliarden…

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.…

Investors need to pay close attention to BMY stock based on the movements in the options market lately.…

Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds…

Cigna accused Bristol Myers Squibb of violating antitrust law by keeping generic versions of its blood cancer drug Pomalyst off the market to…

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that…

^Weitere Gründungsmitglieder sind die European Association of Nuclear Medicine(EANM), GE HealthCare, Novartis und RayzeBio, ein Unternehmen von Bristol MyersSquibb.Wiesbaden, 21.…

^--------------------------------------------------------------------------------Weitere Gründungsmitglieder sind die European Association of Nuclear Medicine(EANM), GE HealthCare, Novartis und RayzeBio, ein Unternehmen von Bristol MyersSquibb.Wiesbaden, …

Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb…

Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior days close.…

Stocks experienced significant volatility this year, which can sometimes make it challenging to keep a positive outlook. In times like…

Dieser Megadeal zwischen Biontech und Brystol-Myers Squibb könnte viel in der Pharma-Branche verändern. Welche Chancen haben Anleger jetzt? Die Chancen…

Artificial intelligence (AI) is playing a disruptive role across several industries as the technology allows businesses, governments, and organizations to…

…

The latest trading day saw Bristol Myers Squibb (BMY) settling at $49, representing a +1.22% change from its previous close.…

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…